Data investigation

The Top Dose Keeps Not Being Worth It

Orforglipron beat an SGLT2 inhibitor on blood sugar and lost badly on tolerability: one in five stopped taking it. And its top dose is the third in a row, across three trials, to buy almost nothing.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·1 citation

A phase 3 trial put oral orforglipron against dapagliflozin, an SGLT2 inhibitor, in 962 people with type 2 diabetes. Orforglipron won on blood sugar and lost badly on tolerability: one in five stopped taking it at the top dose, against one in seventeen on the comparator.[1] That top dose is also the third in a row, across three separate trials, to buy almost nothing.

The trial's own result

Adults with type 2 diabetes inadequately controlled on metformin were randomized across 73 sites to orforglipron at 3, 12 or 36 mg, or dapagliflozin 10 mg, for 40 weeks. Average age was 56.1, average HbA1c 8.14%, and average diabetes duration eight years.

ACHIEVE-2 at 40 weeks, treatment-regimen estimand.[1]
HbA1c changevs dapagliflozinGI eventsStopped treatment
Orforglipron 3 mg−1.23%−0.42%47%15%
Orforglipron 12 mg−1.50%−0.70%46%18%
Orforglipron 36 mg−1.56%−0.75%54%20%
Dapagliflozin 10 mg−0.81%—12%6%

Every orforglipron dose beat dapagliflozin on blood sugar at P<0.0001, and no severe hypoglycemia occurred in any arm. The last two columns are the part that decides a real prescription.

Three quarters of a percentage point of HbA1c, for four times the gut trouble and three times the dropouts.

The pattern across three trials

Look at the 12 mg and 36 mg rows above. Tripling the dose produced 0.06 percentage points more HbA1c reduction and took gastrointestinal events from 46% to 54%.

This is the third time this register has found the same thing, in three separately conducted phase 3 studies, and no single paper points it out because each reports only its own doses.

The top dose against the one below it, in three independent trials.
TrialMiddle doseTop doseWhat the top dose added
ACHIEVE-5 (orforglipron + insulin)12 mg: −1.88%36 mg: −1.82%Nothing — it was slightly worse
ACHIEVE-2 (this trial)12 mg: −1.50%36 mg: −1.56%0.06 percentage points, and 8 more points of GI events
SYNCHRONIZE-1 (survodutide)3.6 mg: −12.2%6.0 mg: −13.0%0.8 points, and GI events from 80.9% to 89.7%
Efficacy plateaus before harm does. In all three trials the top dose added little or nothing over the dose below it, and where gastrointestinal events were reported, the top dose had more of them. So in each of these trials the last step up the titration ladder was the worst-value one. The trials show that shape; they were not designed to explain it.

None of this makes the top dose useless. Higher doses do more for weight in several of these trials even where they do nothing more for blood sugar; the two endpoints plateau at different points, as we set out in the dose that stopped helping. And an individual is not an average: some people need the top dose. The point is that the last step should be a decision rather than a default.

For anyone paying cash for a compounded GLP-1, that decision also has a price side, and it depends on how the seller prices the ladder. 50 Stars Health, Nolu and Edessa charge the same at every dose, so a step up adds nothing to the bill. ReadyRx, Nirwana Health and Metaboost Rx price that way too, and Clume Health sells one all-inclusive monthly program whose molecule is assigned at the evaluation. StackMD works the other way, with its own price for each strength, so every rung costs more than the one below it. FWD Care prices each strength of compounded tirzepatide too, but the climb stops near the top: its member price is $449.99 a month at 10, 12.5 and 15 mg, and members pay $99 a year. Whichever model you are on, the dose stays a call for you and your prescriber, not for the price list.

Orforglipron itself is sold as Foundayo, and its cash price climbs with the dose as well. WeightWatchers bills Foundayo self-pay through LillyDirect, separately from its Med+ membership, and charges more a month at the higher doses than at the starting one. The strengths it lists are not the 3, 12 and 36 mg arms in this trial, so the table above does not line up with a price list. Intermountain Health On-Demand Weight Loss prices Foundayo the same way, from $149 a month at the starting dose and more at higher doses, plus a $49 service fee with each intake.

Why beating dapagliflozin does not settle anything

SGLT2 inhibitors are not a weak comparator chosen to be beaten. They have their own cardiovascular and kidney outcome evidence, they are taken by mouth, they are becoming inexpensive as generics arrive, and in this trial 12% had gastrointestinal side effects against 46–54%.

So a clinician choosing between them is not choosing the one with the better HbA1c. They are weighing three quarters of a percentage point against a threefold difference in the chance the patient abandons treatment. A drug someone stops taking delivers nothing at all.

Whether to use both together is a separate question, and its own disappointing evidence is in why combination therapy fails in practice.

Limits

  • Open-label, though the orforglipron doses were blinded to participants.
  • Forty weeks, in a condition managed for decades, with no cardiovascular or kidney outcomes reported.
  • Funded by Eli Lilly, which develops orforglipron.
  • The discontinuation figures are trial figures. Real-world dropout is generally higher, not lower.

Frequently Asked Questions

For blood sugar, yes. Every dose beat it, by up to 0.75 percentage points of HbA1c. For tolerability, clearly not: gastrointestinal side effects affected 46–54% against 12%, and 15–20% stopped treatment against 6%.
In this trial, tripling from 12 mg to 36 mg improved HbA1c by 0.06 percentage points and raised gastrointestinal events from 46% to 54%. Two other phase 3 trials of two different drugs show the same shape.
The trials show the shape rather than explain it. In each, the benefit had largely flattened by the middle dose, while the top dose brought more gastrointestinal events where those were reported. So in each of these trials the final step up the ladder was the worst-value one.
No. Higher doses do more for weight in several trials even where they do nothing more for blood sugar, and individuals differ from averages. It means the last step should be a decision rather than an automatic default.
That depends on more than HbA1c. SGLT2 inhibitors carry their own cardiovascular and kidney outcome evidence, are far better tolerated here, and are becoming inexpensive. And a drug someone stops taking delivers nothing.

References

  1. 1.Welch M, Forst T, Jia W, et al. Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial The Lancet. 2026. PMID: 42259339.

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

6.4

Bodybuilding Health+

Seeing what it charges before you answer any medical questions

9.0

YourEra

Semaglutide at $99/month, well below the typical price

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →